Neuropace (NPCE) closed at $12.02 on November 12, 2026, down 4.0% from the previous close, on volume of 119,795 shares (30-day average 117,650).
Data as of November 12, 2026.
NeuroPace falls 37% on revenue miss, lowered guidance
Seeking Alpha News (Thu, 12-Nov 5:24 PM ET)
NeuroPace GAAP EPS of -$0.10 in-line, revenue of $23.1M misses by $4.06M
Seeking Alpha News (Thu, 12-Nov 5:24 PM ET)
NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance
Business Wire (Thu, 12-Nov 4:05 PM ET)
NeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026
Business Wire (Thu, 29-Oct 4:05 PM ET)
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
Business Wire (Tue, 1-Sep 5:02 PM ET)
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
Business Wire (Mon, 31-Aug 4:05 PM ET)
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
Neuropace trades on the NASDAQ stock market under the symbol NPCE.
As of November 12, 2026, NPCE stock price declined to $12.02 with 119,795 million shares trading.
NPCE has a beta of 1.16, meaning it tends to be more sensitive to market movements. NPCE has a correlation of 0.07 to the broad based SPY ETF.
NPCE has a market cap of $412.58 million. This is considered a Small Cap stock.
Last quarter Neuropace reported $23 million in Revenue and -$.18 earnings per share. This beat revenue expectation by $163,744 and exceeded earnings estimates by $.01.
In the last 3 years, NPCE traded as high as $19.60 and as low as $5.45.
The top ETF exchange traded funds that NPCE belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
NPCE has underperformed the market in the last year with a price return of -10.9% while the SPY ETF gained +12.0%. NPCE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -20.1% and -7.0%, respectively, while the SPY returned -1.5% and -2.0%, respectively.
NPCE support price is $12.02 and resistance is $13.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NPCE shares will trade within this expected range on the day.